Transforming Acidic Coiled-Coil Containing Protein 3 (TACC3) is a critical regulator of microtubule dynamics, mitotic spindle assembly, and centrosomal integrity. Overexpressed in multiple aggressive malignancies, including glioblastoma, ovarian cancer, and non-small cell lung cancer (NSCLC), TACC3 has emerged as a high-value intracellular target for small-molecule inhibitors, protein-protein interaction (PPI) disruptors, and PROTAC (Proteolysis Targeting Chimera) degraders.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TACC3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TACC3 Recombinant Protein (WT & Mutants) High purity (>90% by SDS-PAGE), sequence-verified, endotoxin-controlled. Available in E. coli or Sf9 insect cell expression systems to preserve structural integrity. |
View TACC3 Products |
| Gene Delivery | TACC3 Lentivirus / Promise-ORF Full-length ORF lentiviral particles optimized for stable cell line generation and phenotypic mitotic arrest assays. |
View TACC3 Products |
| Benchmark Ab | Anti-TACC3 Recombinant Antibody High-affinity sequence-verified positive control antibody for Western Blot, IHC, and immunoprecipitation assays. |
View TACC3 Products |
| Validator | TACC3 siRNA Set Target-specific siRNA pool for target validation and gene knockdown phenotypic comparison. |
View TACC3 Products |
| Related Target A | AURKA (Aurora Kinase A) Key upstream kinase that phosphorylates TACC3 at Ser558, essential for its localization to the mitotic spindle. |
View AURKA Products |
| Related Target B | CKAP5 (ch-TOG) Direct binding partner of TACC3; the TACC3/ch-TOG complex is essential for microtubule stabilization. |
View CKAP5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Evaluating disruption of TACC3/ch-TOG or TACC3/Aurora A interaction | Highly purified, native-conformation recombinant proteins with verified sequence integrity for robust SPR, MST, or AlphaLISA assays. |
| Selectivity screening against TACC family homologs (TACC1, TACC2) | Homolog screening panel featuring highly purified recombinant TACC1 and TACC2 proteins to identify off-target profiles early. |
| Lack of reliable positive controls | Sequence-verified clinical-grade benchmark antibodies and validated siRNA controls included in the development package. |
| Inconsistent phosphorylation-state evaluation | Availability of specific mutant proteins (e.g., phospho-mimetic or phospho-dead mutants) to dissect phosphorylation-dependent interactions. |
Live TACC3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of TACC3 is transitioning from broad mitotic inhibition to highly selective precision oncology. While early microtubule-targeting agents suffered from severe systemic toxicity (such as peripheral neuropathy), next-generation TACC3 therapies focus on disrupting specific protein-protein interactions (such as the TACC3-ch-TOG interface) or utilizing targeted protein degradation (PROTACs) to selectively eliminate TACC3 in rapidly dividing cancer cells. Emerging clinical strategies are evaluating TACC3 inhibitors in combination with established DNA-damaging agents and Aurora Kinase inhibitors to overcome drug resistance pathways in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Biotech Startups | Glioblastoma, Ovarian Cancer | In vitro binding kinetics (Need high-purity, structurally stable recombinant TACC3). |
| PROTAC Degraders | Targeted Therapeutics Specialists | NSCLC, Breast Cancer | Ternary complex formation assays (Need high-purity TACC3 and E3 ligase pathway proteins). |
| RNAi / Antisense | Oligonucleotide Therapeutics Firms | Refractory Solid Tumors | Functional knockdown validation (Need sequence-verified TACC3 siRNA and Lentivirus). |